HAE News Briefs

Hereditary Angioedema

Case Report: Multiple Symptoms in a Patient With HAE and Systemic Lupus Erythematosus

A team from the Division of Hematology, Rheumatology and Respiratory Medicine at Kagawa University in Japan presented the case of a 31-year-old female patient diagnosed with type 1 hereditary angioedema (HAE) and systemic lupus erythematosus (SLE) who developed multiple symptoms. The case report was recently published in Allergy, Asthma & Clinical Immunology. Though SLE is…

Lanadelumab May Be Effective as Long-Term Prophylactic Therapy in Patients With HAE

A new report on 2 patients with hereditary angioedema (HAE) with normal C1-inhibitor (C1-INH) and factor XII mutation (nC1-FXII) found that the administration of lanadelumab, a human immunoglobulin recombinant monoclonal antibody, was effective in preventing attacks. The report, published in the Annals of Allergy, Asthma & Immunology, suggests that larger studies on this medication are…

experimental therapies

HAE Drug Candidate Shows Positive Results in Phase 1/2 Clinical Trial

The clustered regularly interspaced short palindromic repeats (CRISPR)-based genome-editing candidate NTLA-2002 leads to reductions in plasma kallikrein levels and hereditary angioedema (HAE) attacks, according to interim results from a phase 1/2 clinical trial presented at the 2022 Bradykinin Symposium in Berlin, Germany. “These early data support NTLA-2002 as a potential one-time treatment capable of producing…

receptor

Bradykinin B2 Receptor Antagonists May Be Effective in Hereditary Angioedema

Clinical data support the development of bradykinin B2 receptor antagonists for on-demand and prophylactic treatment of hereditary angioedema (HAE), according to a news release by Pharvaris, the company developing two such drugs.  The data were presented at the Bradykinin Symposium 2022 in Berlin, Germany. “Inhibition of bradykinin signaling via B2 receptor antagonism addresses the fundamental…

blood plasma

HAE Drug Candidates Receive Intellectual Property Protection in Europe

The European Patent Office has granted Verseon intellectual property protection covering the company’s plasma kallikrein inhibitors (PKIs) that are being developed for the treatment of hereditary angioedema (HAE) and other chronic conditions. “These novel compounds have unique sets of pharmacological properties that could help hundreds of millions of people around the world,” David Kita, Verseon’s…

pregnant woman

Case Study Suggests Icatibant Is Safe for Pregnant Women With HAE

Researchers from Croatia presented their experience in using icatibant to treat a pregnant patient with hereditary angioedema in a review published in the journal Current Allergy and Asthma Reports.  “Considering the limited number of attacks that our patient usually experiences, which continued at more or less the same frequency during pregnancy, we feel icatibant to…

experimental therapies

Genome-Editing Drug Candidate for HAE Receives Orphan Drug Designation

A new investigational clustered regularly interspaced short palindromic repeats (CRISPR)/Cas 9 gene-editing therapy for the treatment of hereditary angioedema (HAE) has received Orphan Drug designation from the US Food and Drug Administration (FDA).  This is an important milestone for the development of the drug candidate, as it can speed up its approval and entry into…

blood research

Bradykinin Receptor 1 Expression May Play a Role in Hereditary Angioedema

Researchers have discovered that the expression of bradykinin receptor 1 may play an important role in the pathomechanism of hereditary angioedema, according to a study published in the International Journal of Molecular Sciences. Hereditary angioedema is driven by a lack of C1-inhibitor protein, which is caused by mutations in the SERPING1 gene. “C1-inhibitor deficiency causes…

Thrombosis

Patients With HAE Are at an Increased Risk of Thrombotic Events

The association between hereditary angioedema (HAE) and venous thromboembolism (VTE) may be more prominent than initially thought, according to a study recently published in the Journal of Thrombosis and Haemostasis. “In summary, the present study indicates that patients with HAE have a significantly increased risk of composite VTE but not composite [arterial thromboembolism (ATE)],” the…

edema

Prodromes Can Predict Attacks in Patients With Hereditary Angioedema

Researchers in Israel have discovered that prodromes can predict edema attacks in patients with hereditary angioedema, according to a study published on Authorea Preprints. Prodromes are premonitory signs and symptoms that precede an attack. This term is most commonly used to describe the warning signs and symptoms preceding a migraine headache. However, for more than…

Next post in HAE News Briefs